Evidence map›Paper›PMID 35830457›Full record

ArticlePloS one2022

SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations.

Chirag K Kumar, Ruchita Balasubramanian, Stefano Ongarello, Sergio Carmona, Ramanan Laxminarayan

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Routine immunization againstThe Lancet regional health. Southeast Asia · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chirag K KumarPrinceton University, Princeton, NJ, United States of America.
Ruchita BalasubramanianCenter for Disease Dynamics, Economics & Policy, New Delhi, India.
Stefano OngarelloFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Sergio CarmonaFoundation for Innovative New Diagnostics, Geneva, Switzerland.
Ramanan LaxminarayanPrinceton University, Princeton, NJ, United States of America.ORCID 0000-0002-1390-9016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although COVID-19 vaccines are globally available, waning immunity and emerging vaccine-evasive variants of concern have hindered the international response and transition to a post-pandemic era. Testing to identify and isolate infectious individuals remains the most proactive strategy for containing an ongoing COVID-19 outbreak. We developed a stochastic, compartmentalized model to simulate the impact of using Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) assays, rapid antigen tests, and vaccinations on SARS-CoV-2 spread. We compare testing strategies across an example high-income country (the United States) and low- and middle-income country (India). We detail the optimal testing frequency and coverage in the US and India to mitigate an emerging outbreak even in a vaccinated population: overall, maximizing testing frequency is most important, but having high testing coverage remains necessary when there is sustained transmission. A resource-limited vaccination strategy still requires high-frequency testing to minimize subsequent outbreaks and is 16.50% more effective in reducing cases in India than the United States. Tailoring testing strategies to transmission settings can help effectively reduce disease burden more than if a uniform approach were employed without regard to epidemiological variability across locations.

Indexed as

COVID-19SARS-CoV-2COVID-19 TestingCOVID-19 VaccinesDisease OutbreaksHumansUnited StatesCOVID-19 Vaccines

Identifiers

PMID35830457
PMCPMC9278727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.